1.300USD+1.300After-hours (ET)
65.32MMarket Cap
LossP/E TTM
Key Figures
1.230Open
1.310High
147.96KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.30%Turnover Ratio
1.260Prev. Close
1.220Low
156.18KTurnover
LossP/E Static
3.53P/B
0.00%Div Yield TTM
-63.14%ROA
1.57052wk High
0.74Volume Ratio
-13.00MNet Profit
50.05MShares
-0.2748EPS TTM
0.77Beta
-118.40%ROE
0.38052wk Low
7.14%Amplitude
100.00%Gross Margin
65.32MMarket Cap
3.57Reward/Risk
5.60%Risk Rate
Currency: USD Updated: 2026-07-27 Key Insights
Talphera Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 96 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.50.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current strong trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Talphera Inc Highlights
StrengthsRisks
Talphera Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Talphera Inc Info
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Ticker SymbolTLPH
CompanyTalphera Inc
CEOAngotti (Vincent J)
Websitehttps://talphera.com/
Shareholders
FAQs
What is the current price of Talphera Inc (TLPH)?
The current price of Talphera Inc (TLPH) is 1.26.
What is the symbol of Talphera Inc?
The ticker symbol of Talphera Inc is TLPH.
What is the 52-week high of Talphera Inc?
The 52-week high of Talphera Inc is 1.57.
What is the 52-week low of Talphera Inc?
The 52-week low of Talphera Inc is 0.38.
What is the market capitalization of Talphera Inc?
The market capitalization of Talphera Inc is 63.06M.
Is Talphera Inc (TLPH) currently rated as Buy, Hold, or Sell?
According to analysts, Talphera Inc (TLPH) has an overall rating of Buy, with a price target of 3.50.
What is the Earnings Per Share (EPS TTM) of Talphera Inc (TLPH)?
The Earnings Per Share (EPS TTM) of Talphera Inc (TLPH) is -0.34.
